sponsored
PatientsVille.com Logo

PatientsVille

Alemtuzumab Medical Research Studies

Up-to-date List of Alemtuzumab Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Alemtuzumab Medical Research Studies

Rank Status Study
1 Recruiting Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Palifermin;   Drug: Alemtuzumab
Outcome Measures: incidence of clinical autoimmunity;   Absolute numbers of naive T cells;   Safety events
2 Recruiting Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: Alemtuzumab;   Biological: ofatumumab;   Procedure: biopsy
Outcome Measures: Response rates;   Survival rates;   Treatment toxicity as measured by adverse events experienced while on treatment;   Correlation of disease characteristics with disease outcomes;   Compare efficacy between this study and historical control study of Alemtuzumab-rituximab
3 Unknown  Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Alemtuzumab and Rituximab combination
Outcome Measures: Evaluate clinical response of Alemtuzumab and rituximab combination in patients with refractory chronic GVHD based on the Working Group Report 2006.;   Measuring the side effects of Alemtuzumab and rituximab combination through clinical evaluation.;   Measuring the response time achieved with the combination of Alemtuzumab and rituximab through clinical evaluation.
4 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
Outcome Measures: Proportion of patients with a vasculitis response at 6 months;   Proportion of patients with a severe adverse event;   Proportion of patients with treatment failure;   Combined damage assessment (CDA) scores;   Non severe adverse events;   Cumulative dose of corticosteroids;   Time to remission;   Relapse;   Change in SF-36
5 Unknown  Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Drug: Alemtuzumab
Outcome Measure: The primary study objective is to demonstrate whether treatment with Alemtuzumab is effective in stabilizing overall neurocognitive functioning in relapsing-remitting multiple sclerosis over time.
6 Recruiting A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Drug: Alemtuzumab (Campath)
Outcome Measures: Hematologic response (complete or partial) at 3 months after the first dose of Alemtuzumab and sustained on greater than or equal to 2 serial measurements performed 1 month apart.;   Transfusion independence for red blood cells and/or platelets;   Overall survival;   Life-threatening toxicity;   Overall survival and transformation-free survival
7 Unknown  Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Conditions: Peripheral T Cell Lymphoma, Unspecified;   Angioimmunoblastic Lymphadenopathy;   Extranodal NK/T-cell Lymphoma
Interventions: Biological: Alemtuzumab;   Drug: chemotherapy
Outcome Measures: Event free survival;   Rate of complete and partial remissions;   treatment related deaths;   Overall survival;   protocol adherence;   immune reconstitution after Alemtuzumab CHOP
8 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath )
Outcome Measures: Response rate at six months, defined as no longer satisfying blood count criteria for SAA.;   Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia.
9 Recruiting Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Biological: Alemtuzumab
Outcome Measures: Objective Response Rate(ORR);   Progression-Free Survival;   Disease Control Rate(DCR);   Duration of Response(DOR);   Overall Survival;   Summary of patients with Adverse Events(AEs)
10 Recruiting Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
Condition: Chronic Inflammatory Demyelinating Neuropathy
Intervention: Drug: Alemtuzumab infusion
Outcome Measures: Change from baseline in disability at 36 months measured by GBS/CIDP Rasch-built Overall Disability Scale (GBS/CIDP-RODS).;   Change from baseline in disability measured with Overall Neuropathy Limitations Scale (ONLS) at 36 months.
11 Unknown  Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Biological: Alemtuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisolone;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Immediate toxicity (incidence of infusion-related reactions);   Hematopoietic toxicity (number of cycles of therapy associated with neutrophils < 0.5e9/L or platelets < 50e9/L);   Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation);   Disease response (remission rate [complete response and partial response]);   Disease outcome (time to progression and overall survival at 2 years from completion of therapy);   Immune reconstitution (time to recover peripheral blood CD4 count to 0.2 e9/L);   Relative dose intensity;   Pharmacokinetics assessment of Alemtuzumab trough levels before each cycle of treatment;   Epstein-Barr virus copy number (measured retrospectively)
12 Recruiting Alemtuzumab and CHOP in T-cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Interventions: Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with Alemtuzumab;   Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
Outcome Measures: Event-free Survival;   Overall survival;   Overall response rate;   Overall response rate related to the CD52 expression;   Tumor control or time-to-progression;   Safety measured as number of adverse events (AEs) and serious adverse events (SAEs);   Feasibility of successful stem cell harvest i.e. >/=2E6 CD34 positive cells
13 Recruiting Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
Outcome Measures: The primary end point of the study is the response rate at three months, defined as improvement in cytopenia(s);   Secondary endpoints will include relapse-free survival, response at 6 months, life threatening toxicity, reduction in the number of abnormal T-LGL clone, and overall survival.
14 Unknown  Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Conditions: Graft Versus Host Disease;   Bone Marrow Transplantation
Interventions: Drug: Alemtuzumab;   Drug: mycophenolate or cyclosporine and methotrexate
Outcome Measure: Chronic extensive GVHD at 1-year (yes vs. no)
15 Recruiting Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
Condition: Precancerous Condition
Interventions: Biological: Alemtuzumab;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measure: Proportion of patients who achieve greater than 50% donor T-cell chimerism
16 Recruiting Belatacept Early Steroid Withdrawal Trial
Condition: Renal Transplantation
Interventions: Drug: Alemtuzumab;   Drug: rabbit antithymocyte globulin;   Drug: Belatacept;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: early cessation of steroids
Outcome Measures: Composite endpoint;   Secondary endpoint
17 Recruiting Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Conditions: Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide;   Drug: Etoposide;   Drug: Alemtuzumab;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Rituximab;   Drug: Vincristine
Outcome Measures: Assess response, progression free survival (PFS) and overall survival (OS) in relapsed/refractory DLBCL and Hodgkin lymphoma.;   Correlate clinical outcomes with microenvironment/stromal molecular signatures by gene expression profiling and immunohistochemistry on study and at relapse after DA-EPOCH-RC.
18 Unknown  Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Conditions: Infection;   Leukemia
Interventions: Biological: Alemtuzumab;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Dose-limiting toxicity;   Maximum tolerated dose;   Rate of complete minimal residual disease response;   Rate of immunophenotypic remission using 4-color flow cytometry;   Rate of infections (especially CMV infections and reactivations);   Rate of severe hematologic and non-hematologic side effects;   Pharmacokinetics of Alemtuzumab (after IV and subcutaneous administration);   Progression-free survival;   Overall survival;   Complete remission rate
19 Unknown  Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: Alemtuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: flow cytometry;   Other: pharmacological study
Outcome Measures: Toxicity as assessed by NCI Common Toxicity Criteria Version 3.0;   Safety;   Dose-limiting toxicities;   Pharmacokinetics of Alemtuzumab;   Efficacy as assessed by clinical, radiologic, pathologic, and laboratory measurements;   Overall response rate;   Progression-free survival;   Overall survival;   Effects of treatment on T- and B-cell reconstitution by flow cytometry at baseline and at 3, 6, and 12 months
20 Unknown  Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
Condition: Nonmalignant Neoplasm
Interventions: Biological: Alemtuzumab;   Drug: cyclosporine
Outcome Measures: Safety, as defined by occurrence of adverse effects;   Overall survival;   Hematologic response (partial and complete response, including time to response);   Failure-free survival (failure is defined as no response, chronic treatment-maintained response, or relapse);   Incidence of adverse effects after treatment;   Long-term safety of Alemtuzumab treatment;   Time to achieve a complete hematological response;   Proportion of patients maintaining hematological response free of any treatment;   Incidence of relapse in responding patients;   Incidence of severe infections;   Requirement for IV antibiotics and antifungal therapy;   Requirement for red cell and platelet transfusion;   Incidence of CMV reactivation;   Kinetics of immune reconstitution;   Incidence of paroxysmal nocturnal hemoglobinuria (PNH) clone (lymphoid or myeloid) development;   Incidence of clonal evolution (i.e., karyotypic abnormalities or secondary myelodysplasia/leukemia)

These studies may lead to new treatments and are adding insight into Alemtuzumab etiology and treatment.

A major focus of Alemtuzumab research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Alemtuzumab